And Brahmajee K.

In the rivaroxaban group, adherence to therapy was above 80 percent in 94.2 percent of patients. Due to termination of the event-driven study, the procedure duration was significantly less than intended in 125 individuals in the rivaroxaban group and 132 sufferers in the standard-therapy group. A total of 8 patients in the rivaroxaban group and 10 patients in the standard-therapy group were lost to follow-up. Clinical Outcomes The clinical outcomes are shown in Table 3Table 3Clinical Outcomes. Recurrent non-fatal venous thromboembolism was suspected in 491 patients in the rivaroxaban group and in 453 sufferers in the standard-therapy group.Recipients: Members and Staff of the California Society of Health-System Pharmacists, Sacramento, CA. Award for Distinguished Leadership in Health-System Pharmacy Practice The Award for Distinguished Leadership in Health-System Pharmacy Practice recognizes the contributions of practitioners who’ve achieved excellence in health-program pharmacy practice leadership. Recipient: Richard L. Lucarotti, Pharm.D., FASHP, Clinical Director and Professor of Experiential Education, Eugene Applebaum University of Health insurance and Pharmacy Sciences, Wayne State University, Detroit, MI. Table of Directors Award of Honor The ASHP Board of Directors Award of Honor is certainly given to individuals beyond your pharmacy discipline who’ve produced significant contributions to the health field.